mRNA-1283.529

mRNA-1283.529 is a monovalent, next-generation COVID-19 vaccine candidate developed by Moderna. It is an mRNA-based vaccine that encodes the receptor binding domain (RBD) and N-terminal domain (NTD) of the spike protein from the Omicron BA.1 variant of SARS-CoV-2. The vaccine is designed to induce an immune response specifically targeting these regions of the virus's spike protein, which are critical for viral entry into host cells. Like other Moderna COVID-19 vaccines, it uses lipid nanoparticle technology to deliver the mRNA into cells where it can be translated into antigenic proteins that stimulate immunity. The primary indication for this vaccine is prevention of COVID-19.